Research suggests women with high breast cancer risk and menopausal symptoms could benefit from Duavee, which reduced breast ...

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, ...

Recent studies are helping researchers better understand the power of the mind-body connection in treating hot flashes.

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Hot flashes can also be a side effect of antithyroid medications, such as Levothyroxine. In extreme cases, surgery may be necessary to remove the malfunctioning areas of the thyroid gland.

A new treatment for hot flashes brought relief and a better night’s rest for women experiencing these disruptive symptoms during menopause. Two phase 3 clinical trials compared the drug ...

If approved, elinzanetant would be the second nonhormonal drug for the treatment of moderate to severe hot flashes; the FDA approved the first neurokinin 3 receptor antagonist, fezolinetant ...

Instead, hot flash medication — an experimental drug called elinzanetant — doesn’t use hormones and has been shown to reduce hot flashes and improve sleep based on a study from the journal ...

gained approval from the U.S. Food and Drug Administration in 2023 for the treatment of moderate to severe hot flashes. This class of drugs targets a specific type of brain cell called KNDy ...

What nonhormonal medications can help manage hot flashes? Other nonhormonal medications may help people whose hot flashes and night sweats are difficult to manage. The Food and Drug Administration ...

FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box Warning By ... liver markers during the first three months of Veozah treatment and follow-up tests at months six and nine.

The German company’s drug met all the goals of a late-stage study for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes, caused by breast-cancer treatments.